People: Targacept Inc (TRGT.O)

TRGT.O on Nasdaq

2.39USD
27 Apr 2015
Change (% chg)

-- (--)
Prev Close
$2.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
103,155
52-wk High
$4.68
52-wk Low
$2.18

Search Stocks

Hill, Stephen 

Dr. Stephen A. Hill, M.D. has been appointed as President, Chief Executive Officer, Director of Targacept, Inc., effective December 1, 2012. From May 2012 to November 2012, Dr. Hill served as president and chief executive officer of QUE Oncology, a start-up biotechnology company, and, from March 2011 to December 2011, he served as president and chief executive officer of 21st Century Biodefense, Inc., a biodefense company. From April 2008 until its acquisition in December 2010, he served as president and chief executive officer of Solvay Pharmaceuticals, Inc., a pharmaceutical company. Prior to Solvay, he served as president, chief executive officer and director of ArQule, Inc., a pharmaceutical company, from April 1999 to March 2008. Dr. Hill is a member of the board of directors of the publicly-traded companies Cellectar Biosciences, Inc. (formerly Novelos Therapeutics, Inc.) and Lipocine, Inc.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
644,532 -- 693,275 1,677,310

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Richard

--

Stephen Hill

1,677,310

Mauri Hodges

537,958

Patrick Rock

648,543

Scott Cullison

482,885

Charles Blixt

--
As Of  30 Dec 2014
Search Stocks